“IgA Nephropathy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the IgA Nephropathy Market.
The IgA Nephropathy Pipeline report embraces in-depth commercial, regulatory, and IgA Nephropathy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging IgA Nephropathy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
IgA Nephropathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for IgA Nephropathy treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different IgA Nephropathy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major IgA Nephropathy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the IgA Nephropathy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the IgA Nephropathy therapeutic market.
Analysis of Emerging IgA Nephropathy Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the IgA Nephropathy Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight
IgA Nephropathy Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for IgA Nephropathy. Currently, Travere Therapeutics is leading the therapeutics market with its IgA Nephropathy drug candidates in the most advanced stage of clinical development.
IgA Nephropathy Companies Actively Working in the Therapeutic Market Include:
-
Omeros Corporation
-
Novartis Pharmaceuticals
-
Chinook Therapeutics
-
Visterra (a subsidiary of Otsuka Pharmaceutical)
-
Alnylam Pharmaceuticals
-
Vera Therapeutics
-
RemeGen
And Many More
Emerging and Marketed IgA Nephropathy Drugs Covered in the Report Include:
-
Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics initiated a phase III trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.
-
Sparsentan: Travere Therapeutics
Sparsentan is a novel small-molecule candidate in Phase III development for the treatment of IgA nephropathy (IgAN). In March 2022, Travere Therapeutics, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and IgA Nephropathy Companies Working in the Market @
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. IgA Nephropathy Treatment Patterns
4. IgA Nephropathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. IgA Nephropathy Late Stage Products (Phase-III)
7. IgA Nephropathy Mid-Stage Products (Phase-II)
8. IgA Nephropathy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. IgA Nephropathy Discontinued Products
13. IgA Nephropathy Product Profiles
14. Major IgA Nephropathy Companies in the Market
15. Key Products in the IgA Nephropathy Therapeutics Segment
16. Dormant and Discontinued Products
17. IgA Nephropathy Unmet Needs
18. IgA Nephropathy Future Perspectives
19. IgA Nephropathy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Pegfilgrastim Biosimilar Insight
“Pegfilgrastim Biosimilar Insight, 2023” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
